Vor Biopharma (VOR) to Release Earnings on Monday

Vor Biopharma (NYSE:VOR) is scheduled to announce its earnings results on Monday, April 29th.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. On average, analysts expect Vor Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vor Biopharma Stock Down 0.6 %

Shares of NYSE:VOR opened at $1.69 on Friday. The stock has a market capitalization of $115.29 million, a PE ratio of -0.96 and a beta of -0.36. The firm’s 50 day moving average price is $2.01 and its 200-day moving average price is $2.11. Vor Biopharma has a twelve month low of $1.62 and a twelve month high of $5.70.

Analyst Upgrades and Downgrades

Several research firms have weighed in on VOR. HC Wainwright reiterated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price (down from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a research report on Tuesday, April 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, March 22nd. Finally, Stifel Nicolaus cut their price objective on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma currently has an average rating of “Buy” and a consensus target price of $13.50.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.